Analyst Price Targets — CALC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 20, 2024 6:51 am | Leland Gershall | Oppenheimer | $14.00 | $5.45 | StreetInsider | Oppenheimer Reiterates Outperform Rating on CalciMedica (CALC) |
| November 22, 2022 2:31 pm | Christopher Raymond | Raymond James | $392.00 | $146.90 | TheFly | Piper Sandler keeps Neutral on Graybug Vision following CalciMedica merger news |
| May 18, 2022 9:13 pm | Christopher Raymond | Piper Sandler | $392.00 | $171.81 | TheFly | Graybug Vision price target lowered to $2 from $4 at Piper Sandler |
Latest News for CALC
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™ D esign of pivotal program in acute pancreatitis (AP) expected in 1H 2026 JCI Insight publication of preclinical data demonstrates CM5480 as a potential differentiated therapy in pulmonary arterial hypertension (PAH); IND submission…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CALC.
U.S. House Trading
No House trades found for CALC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.